REGENERON PHARMACEUTICALS, INC.(REGN)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
REGENERON PHARMACEUTICALS, INC. (REGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores REGN at 71.0/100 on a 32-signal composite quality model, placing it at rank #203 of 2,960 stocks — the top 10% of the AI-ranked universe. REGN scores in the top quartile across revenue scale (90.6), balance sheet strength (87.1), profitability (83.4). Shareholder dilution risk is elevated at 20.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), REGENERON PHARMACEUTICALS, INC. reports quarterly revenue of $4.3B, net income of $1.3B, an operating margin of 30.1%. Top institutional holders of REGN by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, DODGE & COX, based on the most recent SEC filings. REGN trades on the Nasdaq exchange and files with the SEC under CIK 872589. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate REGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for REGENERON PHARMACEUTICALS, INC. directly from SEC EDGAR.
AI Quality Score
71.0/100
AI Rank
#203
Revenue
$4.3B
Net Income
$1.3B
Free Cash Flow
$572.8M
Operating Margin
30.1%
REGN key financials by period
REGENERON PHARMACEUTICALS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$14.3B
$4.5B
24.9%
FY 2024
10-K
$14.2B
$4.4B
28.1%
FY 2023
10-K
$13.1B
$4.0B
30.9%
FY 2022
10-K
$12.2B
$4.3B
38.9%
FY 2021
10-K
$16.1B
$8.1B
55.7%
FY 2020
10-K
$8.5B
$3.5B
42.1%
Institutions holding REGN
Institutional investors reporting a position in REGENERON PHARMACEUTICALS, INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue reached $4,290.7M as Sanofi collaboration revenue jumped $730.7M on Dupixent, offsetting a 45% decline in U.S. EYLEA sales; net income fell to $1,296.9M.
Higher profits primarily associated with an increase in Dupixent net product sales
Within Collaboration revenue
Sanofi$2,174.3M+$730.7M YoY
Regeneron's share of profits $2,032.6M, 33% of Dupixent and Kevzara net product sales of $6,204.1M
Bayer$276.2M-$138.8M YoY
Lower profits primarily associated with a decrease in EYLEA sales outside the United States
Net product sales$1,642.4M+$11.4M YoY
EYLEA HD and Libtayo volume gains offset by EYLEA declines from competitive pressures and patient transition
Within Net product sales
Total EYLEA HD and EYLEA - U.S.$1,008.5M-$139.0M YoY
EYLEA HD $596.3M on higher volumes; EYLEA $412.2M on lower volumes and lower net selling price
Largest Expense Items
Research and development$1,631.6M+$209.9M YoY
Direct spend rose $85.1M (fianlimab, cenvacibart & amrecibart) and clinical manufacturing costs rose $67.7M
Selling, general, and administrative$662.1M+$27.9M YoY
Higher commercialization-related expenses and headcount costs, offset partly by lower charitable contributions
Cost of goods sold$360.7M+$85.1M YoY
Unabsorbed manufacturing costs from the temporary bulk production interruption in Limerick, Ireland
Cost of collaboration and contract manufacturing$215.8M-$38.8M YoY
Costs of manufacturing drug supplies for collaborators and others
Margins: Gross margin on net product sales fell to 78% from 83%, primarily due to unabsorbed manufacturing costs from a temporary bulk production interruption at Limerick, Ireland; production returned to normal by June 30, 2026.
Watch Items from the Filing
Two distributor customers accounted for 45% and 32% of total gross product revenue in the quarter, versus 52% and 24% a year earlier.
EYLEA U.S. net product sales declined 45% YoY in the quarter to $412.2M on biosimilar and anti-VEGF competition plus transition of patients to EYLEA HD.
Sanofi collaboration revenue, mostly Dupixent profit share, represented 48% of total revenues for the six months ended June 30, 2026, up from 39%.
The Sanofi development balance was fully repaid at June 30, 2026 and will no longer reduce collaboration revenue beginning in the third quarter of 2026.
Acquired in-process R&D expense rose to $127.0M from $10.0M on up-front and opt-in payments, including $50.0M to Parabilis plus $75.0M of its stock.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
